| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Article |




From the Departments of Surgery*
and Immunology
and Pediatrics,§
Mayo Clinic, Rochester,
Minnesota; the Department of Surgery,
Duke
University Medical Center, Durham, North Carolina; and the Universidad
de Navarra,
Pamplona, Spain
Rejection of renal and cardiac xenografts is initiated when natural
antibodies of the recipient bind to donor endothelium,
activating complement on the surface of endothelial cells. Pulmonary
xenotransplants, however, reveal less evidence of
antibody binding and complement activation and, in contrast to
other xenografts, fare worse when the complement of the graft
recipient is depleted. Accordingly, we asked whether distinct
immunochemical reactions might occur after xenotransplantation of the
lung and what implications such reactions might have for pulmonary
pathophysiology. Analysis of serum from baboons after transplantation
with porcine lungs revealed complexes containing baboon IgM and porcine
von Willebrand factor. The baboon IgM in these complexes was specific
for Gal
1-3Gal. Immune complexes were also seen, albeit to a
lesser extent, in the serum of kidney and heart xenotransplant
recipients. Deposits of porcine von Willebrand factor and baboon C3
were detected in livers and spleens of transplanted baboons. These
results indicate pulmonary xenotransplantation eventuates in formation
of immune complexes and in the deposition of those complexes at distant
sites. Immune complex formation could explain the peculiar fate of
xenoreactive antibodies after pulmonary xenotransplantation and might
contribute to the pathophysiology of the lung and systemic changes not
previously considered a complication of
xenotransplantation.
This article has been cited by other articles:
![]() |
H. J. Kang, G. Lee, J. Y. Kim, S. H. Lee, H. C. Wi, P. G. Hwang, D. H. Chung, and Y. T. Kim Pre-treatment of donor with 1-deamino-8-D-arginine vasopressin could alleviate early failure of porcine xenograft in a cobra venom factor treated canine recipient Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 149 - 156. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |